Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 19/20 | 0.51 |
| ▸ | F13A1 | P00488 | 9/20 | 0.51 |
| ▸ | TGM1 | P22735 | 9/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16242097 | 0.82 | TGM2 (0.56) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL16242098 | 0.81 | TGM2 (0.63) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL17979713 | 0.79 | TGM2 (0.61) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL21862103 | 0.79 | MEN1 (0.60) | LMNA | |
| SCHEMBL16653882 | 0.78 | TGM2 (0.59) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL440756 | 0.78 | TGM2 (0.63) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL15669285 | 0.78 | LTA4H (0.59) | — | |
| SCHEMBL439369 | 0.77 | TGM2 (0.79) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL30437401 | 0.77 | KMT2A (0.50) | LMNA | |
| SCHEMBL17621874 | 0.76 | MAPT (0.40) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113209306-A | Antibody drug conjugates with cell permeable BCL-XL inhibitors | 艾伯维公司 | 2021-08-06 | — | — | CN | disclosed |
| EP-3030244-B1 | POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO | ARROWHEAD PHARMACEUTICALS INC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20170022497-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | Arrowhead Pharmaceuticals, Inc. | 2017-01-26 | — | — | US | disclosed |
| US-9487556-B2 | Polyconjugates for delivery of RNAi triggers to tumor cells in vivo | Arrowhead Pharmaceuticals, Inc. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9474804-B2 | Poly(vinyl ester) polymers for in vivo nucleic acid delivery | Arrowhead Pharmaceuticals, Inc. (US) | 2016-10-25 | — | — | US | disclosed |
| US-9452221-B2 | Poly(acrylate) polymers for in vivo nucleic acid delivery | Arrowhead Pharmaceuticals, Inc. (US) | 2016-09-27 | — | — | US | disclosed |
| EP-3030244-A1 | POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO | Arrowhead Research Corporation (US) | 2016-06-15 | — | — | EP | disclosed |
| US-20150283256-A1 | Poly(vinyl ester) Polymers for In Vivo Nucleic Acid Delivery | Arrowhead Pharmaceuticals, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-9089611-B2 | Poly(vinyl ester) polymers for in vivo nucleic acid delivery | Arrowhead Madison Inc. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150110732-A1 | Poly(vinyl ester) Polymers for In Vivo Nucleic Acid Delivery | Arrowhead Madison Inc. | 2015-04-23 | — | — | US | disclosed |
| US-8802773-B2 | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages | Arrowhead Madison Inc. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130317079-A1 | Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery | Arrowhead Madison Inc. (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2658579-A2 | IN VIVO POLYNUCLEOTIDE DELIVERY CONJUGATES HAVING ENZYME SENSITIVE LINKAGES | Arrowhead Research Corporation (US) | 2013-11-06 | — | — | EP | disclosed |
| WO-2013158141-A1 | POLY(ACRYLATE) POLYMERS FOR IN VIVO NUCLEIC ACID DELIVERY | ARROWHEAD RESEARCH CORPORATION (US) | 2013-10-24 | — | — | WO | disclosed |
| US-20130190484-A1 | In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages | Arrowhead Madison Inc. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130121954-A1 | Poly(vinyl ester) Polymers for In Vivo Nucleic Acid Delivery | Arrowhead Madison Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8426554-B2 | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages | Arrowhead Madison Inc. (US) | 2013-04-23 | — | — | US | disclosed |
| WO-2013032829-A1 | POLY(VINYL ESTER) POLYMERS FOR IN VIVO NUCLEIC ACID DELIVERY | ARROWHEAD RESEARCH CORPORATION (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012092373-A2 | IN VIVO POLYNUCLEOTIDE DELIVERY CONJUGATES HAVING ENZYME SENSITIVE LINKAGES | ARROWHEAD RESEARCH CORPORATION (US) | 2012-07-05 | — | — | WO | disclosed |
| US-20120172412-A1 | In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages | Arrowhead Madison Inc. (US) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317079-A1 | Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery | PHAX, PARN, PARG | TGM2 4143/4885F13A1 465/4885TGM1 3985/4885 |
| US-20170022497-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | PAM, PLAUR, M6PR | TGM2 2179/4885F13A1 731/4885TGM1 2555/4885 |
| US-20150283256-A1 | Poly(vinyl ester) Polymers for In Vivo Nucleic Acid Delivery | PHAX, PARG, PABPC4 | TGM2 4118/4885F13A1 617/4885TGM1 3833/4885 |
| US-20120172412-A1 | In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages | RNASE1, PNKP, POLM | TGM2 2078/4885F13A1 1386/4885TGM1 2424/4885 |
| US-20130190484-A1 | In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages | RNASE1, PNKP, POLM | TGM2 2078/4885F13A1 1386/4885TGM1 2424/4885 |
| US-20150110732-A1 | Poly(vinyl ester) Polymers for In Vivo Nucleic Acid Delivery | PHAX, PARG, PABPC4 | TGM2 4118/4885F13A1 617/4885TGM1 3833/4885 |
| US-20130121954-A1 | Poly(vinyl ester) Polymers for In Vivo Nucleic Acid Delivery | PHAX, PARG, PABPC4 | TGM2 4118/4885F13A1 617/4885TGM1 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.